A new study by a counseling researcher at New York Institute of Technology sheds light on the relationship between race and mental health stigma.
MindMed’s Phase 2b Trial For MM-120 in GAD Reaches Enrollment Milestone
MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders, made a noteworthy announcement today. They have